UroGen Pharma Ltd (NASDAQ: URGN) on Tuesday, soared 3.10% from the previous trading day, before settling in for the closing price of $14.51. Within the past 52 weeks, URGN’s price has moved between $10.60 and $24.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 13144.25% annually for the last half of the decade. The company achieved an average annual earnings per share of 4.34%. With a float of $37.26 million, this company’s outstanding shares have now reached $41.17 million.
In an organization with 201 employees, it is important to assess its efficiency.
UroGen Pharma Ltd (URGN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of UroGen Pharma Ltd is 9.50%, while institutional ownership is 78.16%. The most recent insider transaction that took place on Jun 10 ’24, was worth 67,401. In this transaction Chief Medical Officer of this company sold 5,153 shares at a rate of $13.08, taking the stock ownership to the 144,284 shares. Before that another transaction happened on Mar 18 ’24, when Company’s Chief Medical Officer sold 12,000 for $14.05, making the entire transaction worth $168,600. This insider now owns 139,437 shares in total.
UroGen Pharma Ltd (URGN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 4.34% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
UroGen Pharma Ltd (URGN) is currently performing well based on its current performance indicators. A quick ratio of 7.20 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.39, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -2.61 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.42 million. That was inferior than the volume of 0.46 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 19.44%. Additionally, its Average True Range was 0.94.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 43.17%, which indicates a significant increase from 31.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.11% in the past 14 days, which was lower than the 78.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.79, while its 200-day Moving Average is $14.89. However, in the short run, UroGen Pharma Ltd’s stock first resistance to watch stands at $15.81. Second resistance stands at $16.67. The third major resistance level sits at $17.56. If the price goes on to break the first support level at $14.06, it is likely to go to the next support level at $13.17. Assuming the price breaks the second support level, the third support level stands at $12.31.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
Market capitalization of the company is 615.90 million based on 23,454K outstanding shares. Right now, sales total 82,710 K and income totals -102,240 K. The company made 18,780 K in profit during its latest quarter, and -32,290 K in sales during its previous quarter.
